Patel Chem Specialities Ltd
Incorporated in 2008, Patel Chem Specialities Limited (PCSL) is engaged in the manufacturing and exporting of pharmaceutical excipients and specialty chemicals.[1]
- Market Cap ₹ 349 Cr.
- Current Price ₹ 140
- High / Low ₹ 167 / 56.1
- Stock P/E 27.5
- Book Value ₹ 42.5
- Dividend Yield 0.00 %
- ROCE 21.8 %
- ROE 18.6 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 56.9% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.8%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| 42 | 60 | 69 | 82 | 105 | 137 | 153 | |
| Sales growth | +42% | +15% | +19% | +28% | +31% | +31% | |
| 40 | 56 | 64 | 71 | 90 | 120 | 135 | |
| Operating Profit | 2 | 4 | 5 | 12 | 15 | 17 | 18 |
| OPM % | 6% | 7% | 8% | 14% | 15% | 12% | 12% |
| 0 | 0 | 0 | 0 | 0 | 2 | 2 | |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 2 | 4 | 4 | 10 | 14 | 17 | 18 |
| Tax % | 20% | 35% | 30% | 26% | 25% | 26% | |
| 1 | 2 | 3 | 8 | 11 | 13 | 13 | |
| EPS in Rs | 5.91 | 5.05 | 5.10 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 26% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 57% |
| 3 Years: | 63% |
| TTM: | 11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 68% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 28% |
| Last Year: | 19% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 18 | 25 | 25 |
| Reserves | 6 | 8 | 11 | 19 | 18 | 75 | 81 |
| 6 | 8 | 12 | 15 | 14 | 15 | 24 | |
| 5 | 7 | 13 | 12 | 16 | 28 | 27 | |
| Total Liabilities | 18 | 23 | 37 | 47 | 65 | 142 | 156 |
| 6 | 10 | 14 | 14 | 14 | 30 | 30 | |
| CWIP | 0 | 0 | 0 | 2 | 12 | 15 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 13 | 13 | 23 | 31 | 39 | 98 | 104 | |
| Total Assets | 18 | 23 | 37 | 47 | 65 | 142 | 156 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| -24 | 2 | 2 | 6 | 2 | 10 | |
| -1,978 | -4 | -3 | -6 | -7 | -19 | |
| 332 | 0 | 1 | 0 | 5 | 45 | |
| Net Cash Flow | -1,670 | -1 | -0 | 0 | 0 | 36 |
| Free Cash Flow | -24 | -3 | -2 | 3 | -9 | -9 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 13,954% | 56% | 58% | 62% | 32% | 61% |
Ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 56 | 58 | 79 | 68 | 73 | 79 |
| Inventory Days | 15 | 12 | 45 | 64 | 61 | 61 |
| Days Payable | 47 | 35 | 77 | 52 | 51 | 67 |
| Cash Conversion Cycle | 25 | 35 | 47 | 79 | 83 | 73 |
| Working Capital Days | -1 | 6 | 19 | 29 | 57 | 51 |
| ROCE % | 28% | 26% | 39% | 36% | 22% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Export Revenue Share % |
|
||||
| Food Industry Revenue Share % |
|||||
| Installed Capacity Kgs |
|||||
| Sodium CMC Revenue Share % |
|||||
| Capacity Utilization (Aggregate) % |
|||||
| Pharma Industry Revenue Share % |
|||||
| Total Production Volume Kgs |
|||||
| Number of Countries Exported To count |
|||||
Extracted by Screener AI
Documents
Announcements
-
Withdrawal Of Fine Levied Under Regulation 34 Of SEBI (LODR) Regulations, 2015 By BSE Limited.
- BSE withdrew ₹1,22,720 fine for Regulation 34 non-compliance.
-
Board Comments On Levy Of Fine By The Exchange.
- BSE fined Patel Chem ₹1,22,720 for Regulation 34 non-compliance; company seeks waiver.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- H1 FY27 revenue rose 25.07%; Talod capacity expanded to 4,500 MT, with commercial production expected soon.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
- Monitoring agency report for quarter and half year ended September 30, 2026 shows no deviation in IPO fund use.
-
Statement Of Deviation And Variation For The Half Year Ended On 30Th September, 2026
- No deviation in IPO proceeds use for half year ended September 30, 2026; ₹5,880 lakh raised.
Business Profile:[1]
Patel Chem Specialities Limited is engaged in the manufacturing
of cellulose-based excipients used primarily in the pharmaceuticals, food & beverages, cosmetics, and industrial sectors. These products
act as binders, disintegrants, thickeners, stabilizers, and gelling agents across a variety of applications.